Lupus therapeutics announces partnership to support the evaluation of natural killer (nk) cell therapy in lupus nephritis

New york , oct. 17, 2023 /prnewswire/ -- lupus therapeutics, the clinical research affiliate of the lupus research alliance, today announced a partnership with nkarta, inc. (nasdaq: nktx), a biopharmaceutical company developing the engineered natural killer (nk) cell therapy nkx019 for refractory lupus nephritis that has not responded to standard treatment. lupus therapeutics has provided advisory services and will support nkarta in early development through select sites of the lupus clinical investigators network (lucin) comprised of top academic centers throughout north america.
NKTX Ratings Summary
NKTX Quant Ranking